NLS Pharmaceutics Ltd.
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 10 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings, up 2 from Q1 2024. 3 opened new positions and 1 sold out. The largest holders were BVF Inc. ($1.2M), Armistice Capital, LLC ($501K) and UBS Group AG ($51K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830103
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $64K |
| Exits | 1 | $5K |
All 13F filers, Q1 2024 → Q2 2024: 552,314 shares bought and 183,394 shares sold, net +368,920 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| BVF Inc. | 0.03% | No change | 5,747,126 | $1.2M |
| Armistice Capital, LLC | 0.01% | Add +6.4% | 2,311,000 | $501K |
| UBS Group AG | 0.00% | New | 235,723 | $51K |
| Citadel Advisors | 0.00% | Add +610.4% | 136,270 | $30K |
| Jane Street Group, LLC | 0.00% | New | 43,672 | $9K |
| Renaissance Technologies | 0.00% | Reduce -87.9% | 21,777 | $5K |
| Geode Capital Management, LLC | 0.00% | No change | 14,362 | $3K |
| HRT Financial LP | 0.00% | New | 16,832 | $3K |
| Bank of America Corp. | 0.00% | No change | 90 | $19 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.